🚀
Enjoy a 7-Day Free Trial Thru Oct 13, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Strategies Created by Users
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
All Topics
General Discussions
Investment Ideas
Strategies
Article Comments
Books
Feedback
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Drug Manufacturers
Johnson & Johnson (XSGO:JNJ)
News
Johnson & Johnson
XSGO
:JNJ (USA) Â
Ordinary Shares
$ 148.27
(0%)
Oct 4
P/E:
10.01
P/B:
5.39
Market Cap:
$ 385.86B
Enterprise V:
$ 401.87B
Volume:
-
Avg Vol (2M):
-
Warning! GuruFocus detected 4 Medium warning signs with JNJ.
Try a 7-Day Free Trial
to check it out.
Trade In:
Volume:
-
Market Cap $:
385.86B
PE Ratio:
10.01
Avg Vol (2M):
-
Enterprise Value $:
401.87B
PB Ratio:
5.39
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Johnson & Johnson (XSGO:JNJ) Stock News, Headlines & Updates
Johnson & Johnson Stock News from GuruFocus
Total 44
1
2
Oct 04, 2024
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
Business Wire
•
4:00pm
Oct 01, 2024
Unlocking Intrinsic Value: Analysis of Johnson & Johnson
GuruFocus Research
•
6:00am
Sep 30, 2024
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
PRNewswire
•
4:00pm
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
PRNewswire
•
8:00am
Sep 27, 2024
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
PRNewswire
•
4:00pm
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
PRNewswire
•
1:00pm
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
PRNewswire
•
1:00pm
TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
PRNewswire
•
8:00am
Sep 20, 2024
Attorneys Vow to Oppose J&J's Third Bankruptcy Attempt
Business Wire
•
6:00pm
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
Business Wire
•
3:00pm
Sep 16, 2024
Navigating Market Uncertainty: Intrinsic Value of Johnson & Johnson
GuruFocus Research
•
6:00am
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
PRNewswire
•
2:00am
Sep 15, 2024
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
PRNewswire
•
2:00am
Sep 14, 2024
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
PRNewswire
•
9:00am
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
PRNewswire
•
3:00am
Sep 11, 2024
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
PRNewswire
•
6:00pm
Sep 10, 2024
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
PRNewswire
•
5:00pm
Sep 08, 2024
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
PRNewswire
•
1:00pm
Sep 05, 2024
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Business Wire
•
4:00pm
Sep 02, 2024
Unlocking Intrinsic Value: Analysis of Johnson & Johnson
GuruFocus Research
•
6:01am
Aug 29, 2024
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
PRNewswire
•
8:00am
Aug 27, 2024
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
PRNewswire
•
8:00am
Aug 26, 2024
Johnson & Johnson's Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
Business Wire
•
8:00am
Aug 20, 2024
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
PRNewswire
•
7:00am
Johnson & Johnson to Acquire V-Wave
Business Wire
•
7:00am
Aug 19, 2024
Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
GuruFocus Research
•
6:00am
Aug 07, 2024
Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine
PRNewswire
•
4:01pm
Aug 05, 2024
Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
GuruFocus Research
•
6:00am
Jul 30, 2024
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
PRNewswire
•
6:00pm
Jul 29, 2024
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
Business Wire
•
4:00pm
Jul 26, 2024
Courts, Congress Likely to Stand in Way of J&J's Third Texas Two-Step Plan
Business Wire
•
9:00am
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
Business Wire
•
9:00am
Jul 23, 2024
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Business Wire
•
4:00pm
Jul 22, 2024
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy Plan
Business Wire
•
11:00am
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
PRNewswire
•
8:00am
Beyond Market Price: Uncovering Johnson & Johnson's Intrinsic Value
GuruFocus Research
•
6:00am
Jul 18, 2024
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth Amid Competitive Pressures
GuruFocus Research
•
1:01am
Q2 2024 Johnson & Johnson Earnings Call Transcript
GuruFocus Research
•
11:02pm
Jul 17, 2024
Johnson & Johnson's Oncology Strength Drives Q2 Outperformance Despite MedTech Weakness
GuruFocus Research
•
12:14pm
Johnson & Johnson Q2 2024 Earnings: Adjusted EPS Beats Expectations with 10.2% Growth, Revenue Up 4.3%
GuruFocus Research
•
7:31am
Total 44
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news